Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs

See on Scoop.itMyHealthShare Medical Reporter

Jazz Pharmaceuticals Plc (JAZZ), the maker of the narcolepsy treatment Xyrem, said it will buy Gentium SpA (GENT), a rare disease drug developer, in a deal valued at $1 billion. Jazz, based in Dubl…

See on globalgenes.org

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s